Biggest News Aggregation in the World
📰 Recommendation Statement News

Page 3 - Recommendation Statement News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Recommendation Statement. Real-time updates on events, politics, business and more.

Wyndham Board of Directors Sends Letter to Shareholders Highlighting Clear Path to Deliver Value Substantially in Excess of Choice's Inadequate and Risk-Laden Offer

Urges Shareholders to Protect Their Investment and the Future of Wyndham by Supporting Only Wyndhams Eight Highly-Qualified Director Nominees Encourages Shareholders to Visit StayWyndham.com for...
Matt Capuzzi Wyndham Hotels Board Of Directors Wyndham Hotels Resorts Exchange Commission Days Inn Global Communications

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the ...
United States Sujal Shah Bofa Securities Inc Gilead Sciences Cymabay Therapeutics Inc X Twitter Gilead Sciences

MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value

Tafasitamab sold to IncyteNovartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cashShareholders benefit from attractive premium of 94 percent to the one-month volume weighted average price before January 25, 2024Novartis provides ample resources to maximize...
United States Jean Paul Kress Meagher Flom Eamonn Nolan Julia Neugebauer Thomas Biegi

MorphoSys Enters into Business Combination Agreement to be acquired by Novartis for EUR 2.7 Billion Equity Value

Germany - MorphoSys AG today announced the company entered into a Business Combination Agreement with Novartis data42 AG and Novartis AG based on Novartis intention to submit a voluntary public...
United States Thomas Biegi Julia Neugebauer Jean Paul Kress German Federal Financial Supervisory Authority Bafin Company Annual Report On Form

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals

As previously announced on December 22, 2023, Concentra Biosciences, LLC and its wholly owned subsidiary, Concentra Merger Sub II, Inc. , entered into a merger agreement with Theseus...
United States Concentra Merger Sub Ii Inc Concentra Biosciences Theseus Pharmaceuticals Inc Morrow Sodali Broadridge Corporate Issuer Solutions

Wyndham Confirms Receipt of Expansive FTC Second Request Under HSR Act for Choice's Unsolicited Hostile Offer to Acquire Wyndham - Wyndham Hotels & Resorts (NYSE:WH), Choice Hotels Intl (NYSE:CHH)

Extended Regulatory Review Certain Offer Continues to Undervalue Wyndham and Exposes Wyndham Shareholders to Significant Asymmetrical Risk PARSIPPANY, N.J., Jan. 11, 2024 /PRNewswire/ -- Wyndham Hotels & Resorts
Matt Capuzzi Stephenp Holmes Choice Hotels International Inc Prnewswire Wyndham Hotels Resorts Wh Wyndham Hotels Resorts Securities Exchange

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science